You have 9 free searches left this month | for more free features.

ak104

Showing 1 - 25 of 25

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

AK104 Combined With I-125 Brachytherapy for Recurrent or

Not yet recruiting
  • Cervical Cancer
  • Iodine-125 particle brachytherapy
  • AK104
  • (no location specified)
Sep 25, 2023

Advanced Non-small-cell Lung Cancer Trial in Shanghai (AK112, AK104, caboplatin)

Not yet recruiting
  • Advanced Non-small-cell Lung Cancer
  • Shanghai, China
    Shanghai Pulmonary Hospital
Jun 6, 2023

Locally Advanced Rectal Cancer Trial in Guangzhou (AK104, Capecitabine, Neoadjuvant Radiotherapy)

Not yet recruiting
  • Locally Advanced Rectal Cancer
  • AK104
  • +2 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Aug 5, 2023

Muscle Invasive Bladder Carcinoma Trial in Beijing (RC48-ADC, AK104)

Recruiting
  • Muscle Invasive Bladder Carcinoma
  • Beijing, China
    Cancer Institute and Hospital, Chinese Academy of Medical Scienc
Oct 6, 2023

Gastric Cancer Trial in Tianjin (AK104, Apatinib, Paclitaxel)

Recruiting
  • Gastric Cancer
  • AK104
  • +3 more
  • Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
May 7, 2023

Renal Cell Carcinoma, First-line Treatment, Non Clear Cell Renal Cell Carcinoma Trial in Chengdu (AK104, Axitinib)

Not yet recruiting
  • Renal Cell Carcinoma
  • +3 more
  • Chengdu, Sichuan, China
    West China Hospital
Apr 10, 2023

Solid Tumor, Adult Trial in Tianjin (AK119, AK104)

Recruiting
  • Solid Tumor, Adult
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Insitute & Hospital
Dec 28, 2022

Vulvar Cancer Trial in China (AK104)

Not yet recruiting
  • Vulvar Cancer
  • AK104
  • Fuzhou, Fujian, China
  • +5 more
Jun 27, 2023

Pancreatic Cancer Trial in China (AK104, Gemcitabine, Nab-Paclitaxel)

Not yet recruiting
  • Pancreatic Cancer
  • AK104
  • +2 more
  • Beijing, Beijing, China
  • +6 more
May 5, 2023

Esophageal Squamous Cell Carcinoma Trial (AK104)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • AK104
  • (no location specified)
Oct 25, 2022

Carcinomas, Cervix Cancer, Cervical Cancer Trial in Houston (AK104)

Recruiting
  • Carcinomas
  • +2 more
  • AK104
  • Houston, Texas
    M D Anderson Cancer Center
Oct 12, 2022

Hepatocellular Carcinoma Trial in Beijing (AK104, Lenvatinib)

Recruiting
  • Hepatocellular Carcinoma
  • Beijing, Beijing, China
    Chinese PLA General Hospital
Oct 17, 2022

Advanced Malignant Tumors Trial in Shanghai (AK104, AK117, Capecitabine tablets)

Recruiting
  • Advanced Malignant Tumors
  • AK104
  • +8 more
  • Shanghai, China
    Shanghai Renji Hospital
Aug 9, 2022

MSI-H/dMMR Solid Tumor Trial in Guangzhou (AK104)

Terminated
  • MSI-H/dMMR Solid Tumor
  • AK104
  • Guangzhou, Guangdong, China
    Sun Yat-Sen University Cancer Center
Oct 17, 2022

Unresectable, Non-metastatic Hepatocellular Carcinoma Trial in China (biological, drug, procedure)

Recruiting
  • Unresectable, Non-metastatic Hepatocellular Carcinoma
  • AK104
  • +2 more
  • Beijing, Beijing, China
  • +4 more
Aug 11, 2022

NSCLC Trial in Zhengzhou (AK104)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • AK104
  • Zhengzhou, Henan, China
    Henan Cancer Hospital
May 16, 2022

Cervical Cancer Trial in Hanzhong (AK104)

Not yet recruiting
  • Cervical Cancer
  • AK104
  • Hanzhong, Zhejiang, China
    Zhejiang Cancer Hospital
Jan 27, 2022

Locally Advanced Cervical Carcinoma Trial in China (AK104, EBRT, BT)

Recruiting
  • Locally Advanced Cervical Carcinoma
  • AK104
  • +4 more
  • Beijing, Beijing, China
  • +9 more
Aug 22, 2022

Clear Cell Renal Cell Carcinoma, First-line Treatment Trial in Shanghai (AK104, axitinib)

Not yet recruiting
  • Clear Cell Renal Cell Carcinoma
  • First-line Treatment
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Feb 16, 2022

Advanced NSCLC Trial in Nanjing (AK104, Docetaxel)

Recruiting
  • Advanced Non-small Cell Lung Cancer
  • Nanjing, Jiangsu, China
    Jiangsu Cancer Hospital
Mar 24, 2022

Recurrent or Metastatic Cervical Cancer Trial in Changsha, Hangzhou (AK104, Bevacizumab, Paclitaxel)

Active, not recruiting
  • Recurrent or Metastatic Cervical Cancer
  • AK104
  • +3 more
  • Changsha, Hunan, China
  • +1 more
Mar 28, 2022

Cervical Cancer Trial in Hangzhou, Hefei, Shanghai (AK104, paclitaxel, carboplatin)

Recruiting
  • Cervical Cancer
  • AK104
  • +5 more
  • Hangzhou, China
  • +4 more
Apr 26, 2022

Locally Advanced or Metastatic NSCLC Trial in China (AK104, Tislelizumab, carboplatin)

Not yet recruiting
  • Locally Advanced or Metastatic NSCLC
  • AK104
  • +4 more
  • Bengbu, Anhui, China
  • +61 more
Aug 10, 2023

MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer Trial (AK104)

Not yet recruiting
  • MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer
  • AK104
  • (no location specified)
Sep 14, 2020

Gastric Adenocarcinoma, Advanced Solid Tumors, Gastroesophageal Junction Adenocarcinoma Trial in Beijing (AK104, Oxaliplatin,

Unknown status
  • Gastric Adenocarcinoma
  • +2 more
  • AK104
  • +2 more
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Feb 22, 2019